Mobile website
Clinical Research
Intravesical therapy with Bacillus Calmette-Guérin following transurethral resection in patients with superficial bladder cancer: A Meta-analysis of randomized controlled trials
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To systematically evaluate the efficacy and safety of intravesical therapy with Bacillus Calmette-Guérin (BCG) following transurethral resection (TUR) in patients with superficial bladder cancer. Methods：We searched PubMed, EMBASE, the Cochrane Library, Chinese Biomedical Literature Database, Chinese Scientific Journal Full-text Database, and Chinese Journal Full-text Database for randomized controlled trials (RCTs) for studies about intravesical therapy with BCG following TUR in patients with superficial bladder cancer. Two reviewers independently evaluated the quality of the included studies and extracted the data. The data were analyzed using Review Manager 5.0 provided by Cochrane collaboration. Results：Five RCTs (totaling 450 patients) were finally included in the present study. The results showed that there were significant differences in recurrence rates (\[RR=0.64, 95% CI \[0.52, 0.80\]), cystitis ( RR=5063, 95% CI \[14.57, 175.90\]), haematuria (RR=18.28, 95% CI \[5.23, 63.85\]), fever ( RR=2193, 95% CI \[632, 76.02\] ), malaise (RR=10.23, 95% CI \[2.06, 50.81\]), and nausea (RR=4.67, 95% CI \[0.83, 2631\]) between the intravesical therapy with BCG following TUR group and TUR alone group, indicating that intravesical therapy with BCG following TUR was better than TUR alone in preventing the recurrence of bladder cancer, but with more adverse effects. Conclusion：Compared with TUR alone, intravesical therapy with BCG following TUR appears to decrease the tumor recurrence in patients with superficial bladder cancer, but with more adverse effects.
Keywords:
Project Supported:
Clc Number:
